(Q35609674)

9 August 2017

1 reference

title

Current therapy of ulcerative colitis in children (English)

1 reference

9 August 2017

Alan Ronald Bremner

1

1 reference

9 August 2017

David Mervyn Griffiths

series ordinal

2

1 reference

9 August 2017

Robert Mark Beattie

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Pharmacotherapy

9 August 2017

published in

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

37-53

1 reference

Prevalence of gastrointestinal diseases in two British national birth cohorts

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Clinical outcome of ulcerative colitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Treatment of inflammatory bowel disease in childhood: best available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

The value of serologic markers in indeterminate colitis: a prospective follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

The IMPACT Questionnaire: A Valid Measure of Health-Related Quality of Life in Pediatric Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Comparative tolerability of therapies for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Comparative tolerability of the newer fluoroquinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

High-dose azathioprine in children with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Cyclosporin for refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Cyclosporine-Induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Gene transfer approaches for the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Response of refractory colitis to intravenous or oral tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Use of infliximab in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Infliximab as a novel therapy for pediatric ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Infliximab for treatment of steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

A pilot trial of Saccharomyces boulardii in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Reduced bone density in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Evolution of osteopenia in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Lactase deficiency: not more common in pediatric patients with inflammatory bowel disease than in patients with chronic abdominal pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Severe attack of ulcerative colitis in children: retrospective clinical survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Colorectal cancer complicating ulcerative colitis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Colorectal cancer prevention in ulcerative colitis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Diagnosis and management of pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Ileoanal pouch procedures in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Proctocolectomy and J-pouch ileo-anal anastomosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Pediatric ileal pouch-anal anastomosis: functional outcomes and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.37

21 January 2018

Identifiers

DOI

10.1517/14656566.5.1.37

1 reference

release_wmcfrpgwrnfr7mawzoommurthe

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wmcfrpgwrnfr7mawzoommurthe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference